CNC:NYSECentene Corporation Analysis

Centene posted a 21.9% year‑over‑year revenue increase to $49.73 bn in Q4 2025, yet its full‑year revenue guidance of $188.5 bn fell short of consensus and the company posted a non‑GAAP loss of $1.19 per share, slightly worse than expectations. The stock now trades around $36.4, which is dramatically below the DCF‑derived fair value of $371, implying a massive valuation gap. On the balance sheet, cash of $20.3 bn offsets a comparable debt load of $18.2 bn, resulting in a debt‑to‑equity ratio of roughly 90%, while profitability remains weak with a negative operating margin and ROE of –28%. Technicals show the 20‑day SMA (≈42.36) sitting above the 50‑day SMA (≈43.11) and the current price near the identified support of $36.28; the RSI of 31.8 suggests the stock is oversold, though the MACD remains bearish. Recent earnings calls highlighted a potential drop in ACA membership and reaffirmed 2026 EPS guidance, which, despite the earnings miss, was lifted above estimates, fueling mixed sentiment.
Overall, the combination of strong top‑line growth, a deep discount to intrinsic value, and oversold technical conditions creates a short‑term upside catalyst, but the high volatility (≈70% 30‑day), sizable drawdown history (‑60%), and regulatory exposure in the Medicaid/ACA space temper enthusiasm. Investors should weigh the upside from the valuation gap and revenue momentum against the lingering earnings losses, debt burden, and policy risks before deciding on positioning.